TCGFB, a private biotech founded by healthcare VC The Column Group, is tapping California biotech Surrozen to discover antibodies for idiopathic pulmonary fibrosis, according to ...

Sun, M., et al. (2025). Investigation of HO-1 Regulation of Liver Fibrosis Related to Nonalcoholic Fatty Liver Disease Through the SIRT1/TGF-ß/Smad3 Pathway.

BioWorld Content on 'TGF-b' All Clarivate websites use cookies to improve your online experience. They were placed ... link between elevated mechanical tension caused by impaired alveolar regeneration ...

HO-1 inhibits the activation of the TGF-ß/Smad3 pathway in NAFLD-related liver fibrosis through SIRT1. These findings provide insights into new therapeutic strategies for treating NAFLD ...

With 128 TGF-B targeted therapies in the clinic and 68 in the preclinical stage, the TGF-B field is currently being rejuvenated by novel approaches in immuno-oncology, and cutting edge research in ...

In certain cancers, fibrosis is linked to TGF-β-integrin signaling. 59 In scleroderma, the prototypical fibrosing skin disease, skin fibroblasts and myofibroblasts are activated through the TGF ...

Fibrosis: Chronic liver injury triggers persistent TGF-β signaling, leading to the activation of hepatic stellate cells and excessive extracellular matrix production.

Transforming growth factor β1 (TGF-β1) is a key mediator of the fibrotic response, and its dysregulation drives the formation of the fibrotic niche, ... BTI-615 inhibits TGF-β1 signaling and ...

Excessive exosome release is the pathogenic pathway linking a lysosomal deficiency to generalized fibrosis. Science Advances , 2019; 5 (7): eaav3270 DOI: 10.1126/sciadv.aav3270 Cite This Page : ...

About Forbius: Targeting TGF-beta and EGFR Pathways in Fibrosis and Cancer Forbius is a clinical-stage protein engineering company that designs and develops novel biologics for the treatment of ...